Poniard Pharmaceuticals to present its corporate overview

Download PDF Copy

Editorial Checklist

Reviewed

Sep 16 2009

NewsGuard 100/100 Score

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 2009 UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City.

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site.

Source:

http://www.poniard.com

Posted in:

Tags: Biopharmaceutical, Cancer, Cell, Chemotherapy, C-section, Lung Cancer, Oncology, Pharmaceuticals, Small Cell Lung Cancer

Comments (0)

Download PDF Copy

Suggested Reading

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Study uncovers why white button mushrooms may help prevent prostate cancer progression

Study uncovers why white button mushrooms may help prevent prostate cancer progression

VANCE trial marks milestone in t cell therapy for solid tumors

VANCE trial marks milestone in t cell therapy for solid tumors

Early genomic profiling improves cancer treatment outcomes

Early genomic profiling improves cancer treatment outcomes

New drug strategy reverses resistance to immunotherapy in pancreatic cancer

New drug strategy reverses resistance to immunotherapy in pancreatic cancer

MRI-guided SBRT reduces side effects in prostate cancer treatment

MRI-guided SBRT reduces side effects in prostate cancer treatment

Rare genetic mutations in healthy women may be key to breast cancer origins

Rare genetic mutations in healthy women may be key to breast cancer origins

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer